Shandong Jincheng Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
Shandong Jincheng Pharmaceutical Group has a total shareholder equity of CN¥3.8B and total debt of CN¥592.4M, which brings its debt-to-equity ratio to 15.7%. Its total assets and total liabilities are CN¥5.6B and CN¥1.8B respectively. Shandong Jincheng Pharmaceutical Group's EBIT is CN¥221.2M making its interest coverage ratio 54.1. It has cash and short-term investments of CN¥941.3M.
Key information
15.7%
Debt to equity ratio
CN¥592.43m
Debt
| Interest coverage ratio | 54.1x |
| Cash | CN¥941.29m |
| Equity | CN¥3.76b |
| Total liabilities | CN¥1.84b |
| Total assets | CN¥5.60b |
Recent financial health updates
Recent updates
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Shares Bounce 39% But Its Business Still Trails The Market
Oct 08
Estimating The Intrinsic Value Of Shandong Jincheng Pharmaceutical Group Co., Ltd (SZSE:300233)
Oct 07Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Popularity With Investors Is Under Threat From Overpricing
Jun 07Shandong Jincheng Pharmaceutical Group's (SZSE:300233) Problems Go Beyond Weak Profit
Apr 04Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Shares Climb 29% But Its Business Is Yet to Catch Up
Mar 04Shandong Jincheng Pharmaceutical Group (SZSE:300233) Seems To Use Debt Quite Sensibly
Mar 02Financial Position Analysis
Short Term Liabilities: 300233's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥1.3B).
Long Term Liabilities: 300233's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥501.9M).
Debt to Equity History and Analysis
Debt Level: 300233 has more cash than its total debt.
Reducing Debt: 300233's debt to equity ratio has increased from 11.6% to 15.7% over the past 5 years.
Debt Coverage: 300233's debt is well covered by operating cash flow (68.3%).
Interest Coverage: 300233's interest payments on its debt are well covered by EBIT (54.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 01:20 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shandong Jincheng Pharmaceutical Group Co., Ltd is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| YANG QIAO | Changjiang Securities Co. LTD. |
| Chong Chen | Founder Securities Co., Ltd. |